Genomic Response Analysis of Heart Failure Therapy in African Americans

CompletedOBSERVATIONAL
Enrollment

225

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

September 30, 2022

Conditions
Heart Failure
Interventions
DRUG

FDC I/H

All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines

Trial Locations (19)

10461

Montefiore Medical Center Bronx New York, The Bronx

15213

University of Pittsburgh Medical Center, Pittsburgh

19140

Temple University Medical Center, Philadelphia

21201

University of Maryland Medical Center, Baltimore

22903

University of Virginia, Charlottesville

29425

University of South Carolina, Charleston

30310

Morehouse School of Medicine, Atlanta

30322

Emory University, Atlanta

35401

University of Alabama Medical Center, Tuscaloosa

38138

Stern Cardiovascular Foundation, Germantown

44109

MetroHealth System, Cleveland

48202

Henry Ford Health System, Detroit

60611

Northwestern University, Chicago

60612

University of Illinois of Chicago, Chicago

70112

Tulane University Heart and Vascular Institute, New Orleans

70121

Ochsner, New Orleans

77030

Baylor College of Medicine, Houston

02113

Massachsetts General Hospital, Boston

07102

Rutgers University Health Center, Newark

All Listed Sponsors
lead

University of Pittsburgh

OTHER

NCT02305095 - Genomic Response Analysis of Heart Failure Therapy in African Americans | Biotech Hunter | Biotech Hunter